Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/acr.23714 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early neutrophil activation and NETs release in the pristane-induced lupus mice model.
PLoS One
January 2025
Laboratório de Imunologia Celular (LIM-17), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Background: NETosis is recognized as an important source of autoantigens. Therefore, we hypothesized whether the pristane-induced lupus mice model shows early activation of neutrophils, the presence of low-density granulocytes (LDGs), and neutrophil extracellular traps (NETs) release, which could contribute to the development of a lupus phenotype.
Methods: Twelve female wild-type Balb/c mice were intraperitoneally injected with pristane (n = 6; pristane group) or saline (n = 6; control group).
Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women, particularly in African American populations. While its physical health impacts are well-documented, patients also face significant psychosocial burdens, including barriers to healthcare access, financial constraints, mental health challenges, and inadequate social support.
Study Goal: This cross-sectional study surveyed 294 SLE patients recruited from Facebook and Reddit social media forums to examine how demographic factors such as age, race/ethnicity, and geographic location influence these burdens.
The 2024 APLAR Consensus on the Management of Lupus Nephritis.
Int J Rheum Dis
January 2025
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first-line options.
View Article and Find Full Text PDFSerum fatty acid profiles in systemic lupus erythematosus and patient reported outcomes: The Michigan Lupus Epidemiology & Surveillance (MILES) Program.
Front Immunol
January 2025
University of Michigan, Department of Internal Medicine, Ann Arbor, MI, United States.
Introduction: Despite progress in systemic lupus erythematosus (SLE) treatment, challenges persist in medication adherence due to side effects and costs. Precision nutrition, particularly adjusting fatty acid intake, offers a cost-effective strategy for enhancing SLE management. Prior research, including our own, indicates that increased consumption of omega-3 polyunsaturated fatty acids (PUFAs) correlates with improved outcomes in SLE patients.
View Article and Find Full Text PDFThe Genetic Causal Effect of Autoimmune Diseases on pan-Cancers: Evidence from Mendelian Randomization.
J Cancer
January 2025
Department of Spinal Surgery, Tianjin Union Medical Center, Tianjin, China.
Whether autoimmune diseases caused any effects on the risk of cancers remained yet clarified. This study aimed to investigate the causal effect of autoimmune diseases on pan-cancers through mendelian randomization (MR) analysis. The GWAS summary datasets of 10 autoimmune diseases were derived from the IEU or UK biobank website.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!